FHI 059, Version 11	ls	ssued by: FHI	Date of issue: 12/09/2017
Case No: 2019-0388			Date of visit: 08/08/2019
Time spent on site:	hrs	Main Inspecto	or:
Site No: FS1093	Site Name:	Teisti Geo	
Business No: FB0125	Business Name:	Scottish Sea Farms Ltd	
Case Types: 1 SLA	2 3	4 5	6
Water Temp (°C):	Thermometer No:		FHI 045 completed
Observations:	Region: SH	Water type: S	CoGP MA S-11
Dead/weak/abnormally behaving Clinical signs of disease observe Gross pathology observed? Diagnostic samples taken?	•	N If yes, see additional infor	rmation/clinical score sheet. rmation/clinical score sheet. rmation/clinical score sheet.
UNI/REG only - if unable to carry	out intended visit detail	reason below:	

### Additional Case Information:

Thermolicer treatment ongoing during inspection, had been due to complete site the previous day, but treatment delayed due to issue with a compressor onboard the Voe Viking. Thermolicer was reported to be giving good clearances. Sea lice count observed and satisfactory, also conducted eye and skin scores which is standard SSF practice to monitor for any issues with the Thermolicer.

No bath treatments have been conducted this cycle for sea lice, two SLICE treatments have been conducted, one for caligus. Caligus numbers weren't high but treatment conducted due to increase in fish jumping and damaging themselves on top net support. Second SLICE treatment conducted prior to hydrogen peroxide treatment for AGD. Only other sea lice treatments conducted have been 4 Thermolicer treatments.

AGD not reported to be causing any issues this cycle.

Site was fitted with sea lice skirts from two weeks pre input until a couple of weeks ago. Skirts were reported to be effective, no aeration used on site as this can subsequently cause issues during an algal bloom. SSF are reportedly trialling skirts at different depths up to 15m on another site in Shetland.

SSF will have a new Thermolicer boat with all machinery integrated below deck and will be capable of processing higher tonnages per hour than the Voe Viking, which is currently ~70 tonnes per hour..

SSF have also used the Eva Elizabeth, which was reported to be one of the first Thermolicer developed. The system was reported to be very effective. However, unlike the Voe Viking it doesn't filter lice that are removed prior to water being discharge, it utilises electricity to kill the sea lice prior to discharge. Sea water removed during the dewatering step is also filtered on Voe Viking to remove any sea lice that have been dislodged and all filtered water is returned on site. Have reported CMS on site, 3 cages affected, 2 have been harvested and third will be fallow by Monday 12th August. Sites to be stocked by SSF in 3a for next cycle will be Teisti Geo, Holms Geo and Lippie Geo. All will be stocked with 2020 S1 from Barcaldine.

FHI 059, Version 11			Issu	ed by: FHI		Date of issu	e: 12/09/2017		
Case No:	2019-0388		Site No:	FS1093					
Date of Visit:		08/08/201	9		Inspector(s):			]	
Registration/Authorisation Details  1. Business/site details summary checked by site representative?  2. Changes made to details?									
Site Details									
Total No facilities		9	Facilities sto	cked	7	No facilitie	s inspected	9	
Species	SAL	LUM							
Age group	2018 S1	2018							
No Fish	307,617	~36,000							
Mean Fish Wt	4.08 kg	400g							
Next Fallow Date (S	ite)	Oct 2019	_	Next Input Da	ate (Site)	Feb/March	2020		
Recent (last 4 wks)	disease prol	olems?		Y	Any escapes	(since last)	visit)?	N	
If yes, detail:	CMS in cag					`	,		
Movement Record	s								
1. Movement record	ls available f	or inspection	?					Y	
2. Date of last inspe	ection:						26/03/2019		
3. Are records comp		•						Y	
4. Are movement re				•				Y	
5. Are records comp		-						Y	
6. Are health certific	ertificates for introductions (outwith GB) available?							N/A	
Transport Records	Transport Records								
1. Are any moveme	nts carried o	ut by (or on b	ehalf) of the bu	siness (not us	ing a STB)?			Y	
If yes, is there a sys				· ·				Y	
Mortality Records									
Mortality records	available for	inspection?						Y	
2. How are mortaliti	es disposed	of?			Whole fish -	TWMA (She	etland)		
If other detail:									
3. Mortality records complete and correctly entered?									
WK28 - 3,708 (1.02%) attributed to CMS and handling, WK29 - 5,094 (1.419) attributed to CMS, WK30 - 3,369 (0.95%) Attributed to CMS, WK31 - 4,492						, , , , , , , , , , , , , , , , , , , ,			
4. Recent mortality (last 4 wks): (1.34%) attributed to CMS.							N		
Evidence of recent increased/atypical mortalities?  If yes, facility nos/no mortality per facility/no stock per facility/reason:							N		
if yes, facility flos/flo	Thortality pe	r racility/rio si	tock per facility	rieasori.					
6. Any other peaks	in mortality d	uring period o	checked?					N	
If yes, detail:									
7. Have increased (unexplained) mortalities been reported to vet or FHI?							N/A		
If yes, detail action:									
8. Have 'mortality events' been reported to FHI? If no, add MRT case and enter on mortality events sheet.							Y		

FHI 059, Version 11	Issued by: FHI	Date of issue: 12/09/2017
Treatments and Medicines Records		
1. Recent treatments (last 4 wks)?		Y
If the state of th		

Treatments and Medicines Records	
1. Recent treatments (last 4 wks)?	Y
If yes, detail: T.M.S.	
If other, detail:	
2. Medicines records available for inspection?	Y
3. Are records complete and correctly entered?	Y
4. Are fish in a withdrawal period?	Y
5. If yes, what treatment(s)?	
If other, detail:	
6. Are medicines stored appropriately?	Y
Biosecurity Records	
Biosecurity records available for inspection?	
Has the manner and frequency of mortality removal, recording and safe disposal been considered?	
3. Has the manner and period in which the APB will notify Scottish Ministers or veterinary professional of any	
increased (unexplained) mortality at the site been included?	
4. Has the action that will be taken in the event that the presence or suspicion of the presence of a listed disease	
is detected been included and how and when that will be notified to Scottish Ministers?	
5. Has the health status of aquaculture animals being stocked on the farm site been covered (equal or higher	
health status, certification if required)?	
6. Have the husbandry and biosecurity measures implemented between each epidemiological unit to minimise	
transmission of disease been covered (movement of staff, visitors, equipment, live or dead fish etc.)?	
7. Is documentation available regarding the measures in place to maintain the physical containment of aquaculture animals held on site?	
8. Have the biosecurity procedures been adequately implemented on site?	
If no, detail:	
Results of Surveillance	
1. Has any animal health surveillance been carried out by, or on behalf of, the business?	
2. If yes, are results available for inspection?	
3. Any significant results?	
If yes, detail (if not detailed under recent disease problems).	

Records checked between: 26/03/19 to 08/08/19

Case No: 2019-0388	Site No:	FS1093
Date of visit: 08/08/2019	Inspector(s):	

Point for consideration Risk level Satisfactory? Requirement Comments and advice given or action taken if necessary

### **ENHANCED SEA LICE INSPECTION CHECKLIST**

1.1 Are sea lice count records available for inspection? 1.2 Do records adequately reflect the required standard specified in the SSI¹ and the CoGP²? (Counts should be weekly, record the person making the count, date of the count, number of fish sampled (should be 25), pen or facility number recorded, water temperature³, number of parasites observed and correct stages recorded and correct st	a. Inspection of sea lice records				
the SSI¹ and the CoGP²? (Counts should be weekly, record the person making the count, date of the count, number of fish sampled (should be 25), pen or facility number recorded, water temperature³, number of parasites observed and correct stages recorded⁴  1.3 Where weekly counts are not conducted is the reason for not conducting the count stated?  1.4 Is that reason considered acceptable by the Inspector? Give detail.  1.5 Has the site experienced sea lice problems in the previous 4 years?  1.5 Has the site experienced sea lice problems in the previous 4 years?  1.5 Inspection of records relating to treatment and control of sea lice  2.1 Has appropriate action been taken where:  2.1 Has appropriate action been taken where:  2.1 Las appropriate action been taken where:  2.2 Is therapeutic treatment initiated ASAP where required?  2.3 Where medicines have been administered there should be a record of:  2.3 Where medicines have been administered there should be a record of:  2.3 Where medicines have been administered there should be a record of:  2.3 Where medicines have been administered there should be a record of:  4 High Y H	1.1 Are sea lice count records available for inspection?	Medium	Υ	CoGP 1.2.1, 1.2.2,	
(Counts should be weekly, record the person making the count, date of the count, number of fish sampled (should be 25), pen or facility number recorded, water temperature <sup>3</sup> , number of parasites observed and correct stages recorded <sup>4</sup> 1.3 Where weekly counts are not conducted is the reason for not conducting the count stated?  1.4 Is that reason considered acceptable by the Inspector? Give detail.  1.5 Has the site experienced sea lice problems in the previous 4 years?  1.5 Has the site experienced sea lice problems in the previous 4 years?  1.5 Has the site experienced sea lice problems in the previous 4 years?  2.1 Has appropriate action been taken where:  2.1 Has appropriate action been taken where:  3) L. selmonis record levels have been above the suggested criteria for treatment?  3) CoGP Annex 6  4 High  7 CoGP 4.3.130, 5.3.84  Medium  Y CoGP 4.3.130, 5.3.84  This has been complicated by the on-going CMS challenge on site, and plan to minimise handling of stock to minimise mortalities. Plan to harvest site to reduce biomass.  2.3 Where medicines have been administered there should be a record of:  the name / identity of the product the date of administration  the quantity (concentration and amount) administered  High  Y	1.2 Do records adequately reflect the required standard specified in	Low & Medium	Υ		
of the count, number of fish sampled (should be 25), pen or facility number recorded, water temperature <sup>3</sup> , number of parasites observed and correct stages recorded <sup>4</sup> 1.3 Where weekly counts are not conducted is the reason for not conducting the count stated?  1.4 Is that reason considered acceptable by the Inspector? Give detail.  1.5 Has the site experienced sea lice problems in the previous 4 years?  1.6 Inspection of records relating to treatment and control of sea lice  2.1 Has appropriate action been taken where:  3.1 L salmonis record levels have been above the suggested criteria for treatment?  3.2 L salmonis record levels have been above the suggested criteria for treatment?  3.3 Where medicines have been administered there should be a record of:  4.4 Is that reason considered to cause significant will be conducted following week  4.5 Inspection of records relating to treatment and control of sea lice  2.1 Has appropriate action been taken where:  3.1 L salmonis record levels have been above the suggested criteria for treatment?  4.5 CoGP 4.3.81, 5.3.50  4.6 Medium  4.7 CoGP 4.3.81, 5.3.50  4.8 This has been complicated by the on-going CMS challenge on site, and plan to minimise handling of stock to minimise mortalities. Plan to harvest site to reduce blomass.  2.3 Where medicines have been administered there should be a record of:  4.7 High  4.8 High  5.8 High  7.8 High  8.9 High  9. High  1.9 High  1.9 High  1.9 High  1.9 High  1.9 High  1.0 High  1.0 High  1.1 High  1.2 High  1.3 High  1.3 High  1.4 High  1.5 High  1	the SSI <sup>1</sup> and the CoGP <sup>2</sup> ?			SSI 1,2,	
number recorded, water temperature <sup>3</sup> , number of parasites observed and correct stages recorded <sup>4</sup> 1.3 Where weekly counts are not conducted is the reason for not conducting the count stated? 1.4 Is that reason considered acceptable by the Inspector? Give detail. 1.5 Has the site experienced sea lice problems in the previous 4 years?  b. Inspection of records relating to treatment and control of sea lice 2.1 Has appropriate action been taken where: a) L. salmonis record levels have been above the suggested criteria for treatment? b) C. elongatus infestation is at a level considered to cause significant welfare problems 2.2 Is therapeutic treatment initiated ASAP where required?  Medium  Medium  Y CoGP 4.3.130, 5.3.84  This has been complicated by the on-going CMS challenge on site, and plan to minimise handling of stock to minimise mortalities. Plan to harvest site to reduce biomass.  2.3 Where medicines have been administered there should be a record of: the date of administration the date of administration the quantity (concentration and amount) administered  High High High High High High High Hig	(Counts should be weekly, record the person making the count, date				
and correct stages recorded 1.3 Where weekly counts are not conducted is the reason for not conducting the count stated? 1.4 Is that reason considered acceptable by the Inspector? Give detail.  1.5 Has the site experienced sea lice problems in the previous 4 years?  1.5 Inspection of records relating to treatment and control of sea lice 2.1 Has appropriate action been taken where: a) L. salmonis record levels have been above the suggested criteria for treatment? b) C. elongatus infestation is at a level considered to cause significant welfare problems 2.2 Is therapeutic treatment initiated ASAP where required?  Medium  Y  Detail if necessary:  Y  Detail if necessary:  Y  Detail if necessary:  Y  CoGP Annex 6  CoGP 4.3.81, 5.3.50  Welfur Problems  CoGP 4.3.81, 5.3.50  Welfur Problems  1.5 High With Problems  2.6 In the graph of the product the date of administration the quantity (concentration and amount) administered  Y  N/MD 12 19  SSI 1.3  Y  This has been complicated by the on-going CMS challenge on site, and plan to minimise handling of stock to minimise mortalities. Plan to harvest site to reduce blomass.	of the count, number of fish sampled (should be 25), pen or facility				
1.3 Where weekly counts are not conducted is the reason for not conducting the count stated?  1.4 Is that reason considered acceptable by the Inspector? Give detail.  1.5 Has the site experienced sea lice problems in the previous 4 years?  b. Inspection of records relating to treatment and control of sea lice  2.1 Has appropriate action been taken where:  a) L. salmonis record levels have been above the suggested criteria for treatment?  b) C. elongatus infestation is at a level considered to cause significant welfare problems  2.2 Is therapeutic treatment initiated ASAP where required?  Medium  Medium  Y  Detail if necessary:  Y  Detail if necessary:  Y  CoGP Annex 6  Y  CoGP Annex 6  This has been complicated by the on-going CMS challenge on site, and plan to minimise handling of stock to minimise mortalities. Plan to harvest site to reduce biomass.  2.3 Where medicines have been administered there should be a record of:  the date of administration the date of administration the quantity (concentration and amount) administered  Low  Y  Detail if necessary:  Y  CoGP Annex 6  CoGP 4.3.81, 5.3.50  This has been complicated by the on-going CMS challenge on site, and plan to minimise handling of stock to minimise mortalities. Plan to harvest site to reduce biomass.	number recorded, water temperature <sup>3</sup> , number of parasites observed				
conducting the count stated?  1.4 Is that reason considered acceptable by the Inspector? Give detail.  1.5 Has the site experienced sea lice problems in the previous 4 years?  1.6 Inspection of records relating to treatment and control of sea lice  2.1 Has appropriate action been taken where:  a) L. salmonis record levels have been above the suggested criteria for treatment?  b) C. elongatus infestation is at a level considered to cause significant welfare problems  2.2 Is therapeutic treatment initiated ASAP where required?  Medium  Medium  Y  CoGP 4.3.130, 5.3.84  This has been complicated by the on-going CMS challenge on site, and plan to minimise handling of stock to minimise mortalities. Plan to harvest site to reduce biomass.  2.3 Where medicines have been administered there should be a record of: the name / Identity of the product the date of administration the quantity (concentration and amount) administered  Low  Y  Detail if necessary:  CoGP Annex 6  CoGP Annex 6  CoGP 4.3.81, 5.3.50  Wedium  Y  CoGP 4.3.81, 5.3.50  This has been complicated by the on-going CMS challenge on site, and plan to minimise handling of stock to minimise mortalities. Plan to harvest site to reduce biomass.	and correct stages recorded <sup>4</sup>				
1.4 Is that reason considered acceptable by the Inspector? Give detail.  1.5 Has the site experienced sea lice problems in the previous 4 years?  1.6 Las appropriate action been taken where: 2.1 Has appropriate action been taken where: 3.1 L. salmonis record levels have been above the suggested criteria for treatment?  2.2 Is therapeutic treatment initiated ASAP where required?  2.3 Where medicines have been administered there should be a record of:  2.4 High Y CoGP 4.3.130, 5.3.84  This has been complicated by the on-going CMS challenge on site, and plan to minimise handling of stock to minimise mortalities. Plan to harvest site to reduce biomass.		Low	Υ	SSI 1,2(g)	
detail.  1.5 Has the site experienced sea lice problems in the previous 4 years?  Detail if necessary:    Detail if necessary:					
1.5 Has the site experienced sea lice problems in the previous 4 years?  b. Inspection of records relating to treatment and control of sea lice 2.1 Has appropriate action been taken where: a) L. salmonis record levels have been above the suggested criteria for treatment? b) C. elongatus infestation is at a level considered to cause significant welfare problems 2.2 Is therapeutic treatment initiated ASAP where required?  Medium  Medium  Y  CoGP 4.3.130, 5.3.84  This has been complicated by the on-going CMS challenge on site, and plan to minimise handling of stock to minimise mortalities. Plan to harvest site to reduce blomass.  2.3 Where medicines have been administered there should be a record of: the name / identity of the product the date of administration the quantity (concentration and amount) administered  Y  Detail if necessary:  Y  CoGP 4.3.13 if necessary:  Detail if necessary:  Y  CoGP 4.3.81, 5.3.50  This has been complicated by the on-going CMS challenge on site, and plan to minimise handling of stock to minimise mortalities. Plan to harvest site to reduce blomass.	1.4 Is that reason considered acceptable by the Inspector? Give	Low	Υ		,
years?  b. Inspection of records relating to treatment and control of sea lice  2.1 Has appropriate action been taken where: a) L. salmonis record levels have been above the suggested criteria for treatment? b) C. elongatus infestation is at a level considered to cause significant welfare problems  2.2 Is therapeutic treatment initiated ASAP where required?  Medium  Y  CoGP 4.3.81, 5.3.50  Welfare problems  2.2 Is the required initiated ASAP where required?  Medium  Y  CoGP 4.3.130, 5.3.84  This has been complicated by the on-going CMS challenge on site, and plan to minimise handling of stock to minimise mortalities. Plan to harvest site to reduce blomass.  VMD <sup>12</sup> 19 SSI 1,3  This has been complicated by the on-going CMS challenge on site, and plan to minimise handling of stock to minimise mortalities. Plan to harvest site to reduce blomass.					will be conducted following week
b. Inspection of records relating to treatment and control of sea lice  2.1 Has appropriate action been taken where: a) L. salmonis record levels have been above the suggested criteria for treatment? b) C. elongatus infestation is at a level considered to cause significant welfare problems  2.2 Is therapeutic treatment initiated ASAP where required?  Medium  Medium  Y  CoGP 4.3.81, 5.3.50  This has been complicated by the on-going CMS challenge on site, and plan to minimise handling of stock to minimise mortalities. Plan to harvest site to reduce biomass.  2.3 Where medicines have been administered there should be a record of: the name / identity of the product the date of administration the quantity (concentration and amount) administered  High Y  High N/A  High			Υ	Detail if necessary:	
2.1 Has appropriate action been taken where: a) L. salmonis record levels have been above the suggested criteria for treatment? b) C. elongatus infestation is at a level considered to cause significant welfare problems  2.2 Is therapeutic treatment initiated ASAP where required?  Medium  Medium  Y  CoGP 4.3.81, 5.3.50  This has been complicated by the on-going CMS challenge on site, and plan to minimise handling of stock to minimise mortalities. Plan to harvest site to reduce biomass.  2.3 Where medicines have been administered there should be a record of: the name / identity of the product the date of administration the quantity (concentration and amount) administered  High Y  CoGP 4.3.81, 5.3.50  This has been complicated by the on-going CMS challenge on site, and plan to minimise handling of stock to minimise mortalities. Plan to harvest site to reduce biomass.  VMD <sup>12</sup> 19 SSI 1,3  Y  the date of administration High High High High High High High High					
a) L. salmonis record levels have been above the suggested criteria for treatment? b) C. elongatus infestation is at a level considered to cause significant welfare problems  2.2 Is therapeutic treatment initiated ASAP where required?  Medium  Y  CoGP 4.3.81, 5.3.50  Medium  Y  CoGP 4.3.130, 5.3.84  This has been complicated by the on-going CMS challenge on site, and plan to minimise handling of stock to minimise mortalities. Plan to harvest site to reduce biomass.  2.3 Where medicines have been administered there should be a record of: the name / identity of the product the date of administration the quantity (concentration and amount) administered  High Y  CoGP 4.3.81, 5.3.50  This has been complicated by the on-going CMS challenge on site, and plan to minimise handling of stock to minimise mortalities. Plan to harvest site to reduce biomass.  VMD <sup>12</sup> 19 SSI 1,3  High Y  High Y  High Y  High High Y		ce			
for treatment? b) C. elongatus infestation is at a level considered to cause significant welfare problems 2.2 Is therapeutic treatment initiated ASAP where required?  Medium  Y  CoGP 4.3.81, 5.3.50  This has been complicated by the on-going CMS challenge on site, and plan to minimise handling of stock to minimise mortalities. Plan to harvest site to reduce biomass.  2.3 Where medicines have been administered there should be a record of: the name / identity of the product the date of administration the quantity (concentration and amount) administered  High Y  High Y  High Y	• • •				
b) C. elongatus infestation is at a level considered to cause significant welfare problems  2.2 Is therapeutic treatment initiated ASAP where required?  Medium  Y  CoGP 4.3.81, 5.3.50  This has been complicated by the on-going CMS challenge on site, and plan to minimise handling of stock to minimise mortalities. Plan to harvest site to reduce biomass.  2.3 Where medicines have been administered there should be a record of: the name / identity of the product the date of administration the quantity (concentration and amount) administered  High Y  High Y  High Y		High	Υ	CoGP Annex 6	
welfare problems  2.2 Is therapeutic treatment initiated ASAP where required?  Medium  Y  CoGP 4.3.130, 5.3.84  This has been complicated by the on-going CMS challenge on site, and plan to minimise handling of stock to minimise mortalities. Plan to harvest site to reduce biomass.  2.3 Where medicines have been administered there should be a record of: the name / identity of the product the date of administration the quantity (concentration and amount) administered  High Y  High Y					
2.2 Is therapeutic treatment initiated ASAP where required?  Medium  Y  CoGP 4.3.130, 5.3.84  This has been complicated by the on-going CMS challenge on site, and plan to minimise handling of stock to minimise mortalities. Plan to harvest site to reduce biomass.  VMD <sup>12</sup> 19 SSI 1,3  This has been complicated by the on-going CMS challenge on site, and plan to minimise handling of stock to minimise mortalities. Plan to harvest site to reduce biomass.  VMD <sup>12</sup> 19 SSI 1,3  This has been complicated by the on-going CMS challenge on site, and plan to minimise handling of stock to minimise mortalities. Plan to harvest site to reduce biomass.		High	N/A	CoGP 4.3.81, 5.3.50	
plan to minimise handling of stock to minimise mortalities. Plan to harvest site to reduce biomass.  2.3 Where medicines have been administered there should be a record of: the name / identity of the product the date of administration the quantity (concentration and amount) administered  Plan to minimise handling of stock to minimise mortalities. Plan to harvest site to reduce biomass.  VMD <sup>12</sup> 19 SSI 1,3  High Y High Y High Y	· · · · ·	Medium	Υ	CoGP 4 3 130 5 3 84	This has been complicated by the on-going CMS challenge on site, and
2.3 Where medicines have been administered there should be a record of: the name / identity of the product the date of administration the quantity (concentration and amount) administered  harvest site to reduce biomass.  VMD <sup>12</sup> 19 SSI 1,3  Y  High Y  High Y	2.2 is therepeated a cathletic initiation / 10/11 Where required:	Wedam	ľ	4.0.100, 0.0.04	
record of: the name / identity of the product the date of administration the quantity (concentration and amount) administered High Y  High Y					
record of: the name / identity of the product the date of administration the quantity (concentration and amount) administered High Y  High Y					
the name / identity of the product the date of administration the quantity (concentration and amount) administered  High Y  High Y  High Y	2.3 Where medicines have been administered there should be a			VMD <sup>12</sup> 19	
the date of administration High Y the quantity (concentration and amount) administered High Y	record of :			SSI 1,3	
the quantity (concentration and amount) administered  High	the name / identity of the product	High	Υ		
	the date of administration	High	Υ		
the mostle of the distriction of the most set.	the quantity (concentration and amount) administered	High	Υ		
the method of administration of the product High Y	the method of administration of the product	High	Υ		
the identification of the fish / facilities treated High Y	the identification of the fish / facilities treated	High	Υ		
name of the person administering the treatment Low Y	name of the person administering the treatment	_	Υ		
the withdrawal period Medium Y		Medium	Υ		
2.4 If the medicine is administered by a veterinary surgeon:  VMD 18	2.4 If the medicine is administered by a veterinary surgeon:			VMD 18	

Point for consideration	Risk level	Satisfactory?	Requirement	Comments and advice given or action taken if necessary
the name of the veterinary surgeon	High	N/A	requirement	Comments and davice given or action taken in necessary
name of the product	High	N/A	1	
batch number	High	N/A	1	
the date of administration	High	N/A	1	
amount administered	High	N/A		
identification of fish treated	High	N/A	1	
withdrawal period	Medium	N/A	1	
2.5 Have therapeutic treatments or the actions taken had a significant impact upon the lice levels recorded?	High	Υ		
Inspect records to confirm. Significant impact - ≥50% reduction in site average <i>L.salmonis</i> numbers (all stages)				
2.6 If other methods are employed on site to control sea lice and their impact is there a record of:	Low	Y	SSI, 1,4	Thermolicer used for treatments, Lumpsucker stocked on site.
the nature and date of the method employed; the identification number of all facilities subjected to the method; the name of the person employing the method				
2.7 Where medicines have been acquired is there a record of:			VMD 19	
proof of purchase of the medicine concerned	Medium	Υ	VMD 17	
name of the product	High	Υ		
batch number	High	Υ		
the date of purchase	Medium	Υ		
the quantity purchased	High	Υ		
the name and address of the supplier	Medium	Υ		
2.8 Where medicines have been disposed is there a record of:			VMD 19	
the date of disposal	Medium	N/A		
the quantity of product involved	Medium	N/A		
how and where it was disposed of	Medium	N/A		
2.9 Are veterinary health plans available which detail bio-security	Medium	Υ	CoGP 4.3.129, 5.3.83	
protocols, preventative measures and treatments in relation to sea lice?				
Consider the following points over a percentage of treatments conducted on site				
2.10 Has the recommended course of treatments been completed?	Medium	Υ	CoGP 4.3.134, 5.3.88	
2.11 If not, is there a recorded acceptable reason for not completing treatment?	Medium	N/A	CoGP 4.3.135, 5.3.89	
2.12 Was advice taken from the Veterinary surgeon in such circumstances?	Medium	N/A	CoGP 4.3.135, 5.3.89	

Point for consideration	Risk level	Satisfactory?	Requirement	Comments and advice given or action taken if necessary
2.13 Are there clear written instructions regarding medicine use, available to those responsible for treatment administration?	Medium	Υ	CoGP 4.3.133, 5.3.87	
2.14 Does the site have treatment discharge consents relevant to sea lice?		Υ	Detail if necessary:	
c. Inspection of records relating to farm management groups and	farm managen	nent agreements	or statements	
3.1 Is there a nominated farmer acting as coordinator and point of contact for this farm or area inclusive of this farm?	Low	Υ	SSI 1,5,b CoGP 4.3.75, 5.3.44	Fish Health and Welfare manager.
3.2 Is there a written undertaking that the farm will observe the provisions of the NTS <sup>6</sup> ?	Low	Υ	CoGP 4.3.76, 5.3.45	
3.3 Has an area group been formed within the area containing the site?	Medium	Υ	CoGP 4.3.77, 5.3.46	Fish Health group formed for Shetland which includes SSF, GSS and CAS.
3.4 Does the remit of the area group have appropriate veterinary involvement? Consider: -agreed basis for monitoring sea lice -coordinated monitoring and treatment -co-operation between participating farms	Medium	Y	CoGP 4.3.77, 5.3.46 SSI 1,5, c	
This may require follow up investigation conducted off site to determine			1	
3.5 Are records available of any decisions made by the FMG in relation to the prevention, control and reduction of parasites?	Low	Υ	SSI 1, 5, c	Regular fish health meetings for Shetland
3.6 Where treatments have been administered is this done in accordance with principles to maximise the effectiveness of treatments, promote the minimal use of medicines consistent with the maintenance of high standards of fish welfare and help preserve their efficacy?	Medium	Υ	4.3.82, 5.3.51	
For example, the principles of ISLM include: Resistance monitoring – reporting suspected adverse drug event (SADE) to the VMD.				
The steps to determine if resistance is considered a reason for a suspected lack of efficacy (e.g. Bio-assay tests and results, seeking veterinary advice)				
Appropriate discharge consent in place Use of authorized medicines with veterinary instruction and advice as necessary				
Monitoring lice numbers Using an array of treatments where possible Treating all stocks on site at the same time				
Avoiding the simultaneous use of different active ingredients  Avoiding consecutive treatments of the same active ingredient, and certainly not on the same cohort of lice				

Point for consideration	Risk level	Satisfactory?	Requirement	Comments and advice given or action taken if necessary
Routine removal of moribund fish and regular removal of mortalities.				
3.7 Are weekly monitoring results communicated to other farmers within the defined area?	High	Υ	CoGP 4.3.78, 5.3.47	
3.8 Is this done 'as soon as reasonably possible where lice numbers exceed the suggested criteria for treatment?	High	Υ	CoGP 4.3.79, 5.3.48	
3.9 Is sea lice data and other information relevant to the management of sea lice provided to the SSPO?	Low	Υ	CoGP 4.3.80, 5.3.49	
3.10 Are annual review meetings held by FMA groups to evaluate site performance against set criteria?	High	Υ	CoGP 4.3.83, 5.3.52	Discussed whilst reviewing FMAg.
3.11 Is there a signed documented farm management agreement or		Υ	AFSA <sup>13</sup> 4A	
farm management statement relevant to the site and CoGP Farm				
Management Area (or equivalent)?			Detail if necessary:	
3.12 Are up to date copies of FMS available from other APB operating within the same FMA?	Medium	N/A	CoGP 4.3.88, 5.3.57	FMAg in place between SSF and GSS.
3.13 Are significant changes to FMS notified to other companies within the FMA?	Medium	N/A	CoGP 4.3.89, 5.3.58	
3.14 Is there co-operation between APB's operating within the FMA in the development and implementation of FMAg?	Medium	N/A	CoGP 4.3.90, 5.3.59	Already FMAg in place
3.15 Are copies of FMS or FMAg available for inspection?	Medium	Υ	AFSA 4B	FMAg for current cycle, due for review prior to restocking at beginning 2020.
3.16 Does the FMS or FMAg take into account the relevant aspects regarding a sea lice control strategy?	Medium	Y	CoGP 4.3.91, 5.3.60	
3.17 If the FMA has been redefined, is there documented evidence to demonstrate that the risks to health within and outwith the area is not increased by the proposal?	High <sup>10</sup>	N/A	CoGP 4.3.92, 5.3.61	
3.18 Is the CoGP Farm Management Area (or equivalent) fallowed synchronously on a single year class basis?	High	Υ	CoGP 4.3.100	
3.19 If answered no to 3.18, then is there a documented risk	High	N/A	CoGP 4.3.101	
assessment which meets the requirements of CoGP point 4.3.101?	ŭ			
d. Inspection of records relating to training and procedures				
4.1 Is there a training programme or plan in place relevant to sea lice	High	Υ	CoGP 7.1.8	NAFC training course covers sea lice
control for the site?				
4.2 Are training records available for relevant staff in relation to:			CoGP 4.1.6, 5.1.6 SSI, 1,1	
parasite identification	High	Υ	CoGP 4.3.84-86,	
counting parasites (procedures for)	High	Υ	5.3.53-55	
recording counts	High	Υ		
biology and life cycle of parasites	Low	Υ		
symptoms of parasite infection in fish	Low	Υ		

THI 659, VEISION TI		issued by	,. I I II	Date of 133de. 12/00/201
Point for consideration	Risk level	Satisfactory?	Requirement	Comments and advice given or action taken if necessary
4.3 Have staff been trained in the administration of treatments?	High	Υ	CoGP 4.1.6, 5.1.6	
			CoGP 4.3.84, 5.3.53	
N.B. there is no legal requirement to maintain a record of this				
Where records exist regarding SOPs and site procedures these				
should be inspected to confirm suitability				
e. Inspection of site and site stock				
5.1 Are medicines used, stored and disposed of safely?	Medium	Υ	VMD schedule 5	
5.2 Do the sea lice levels observed on stocks reflect sea lice count	High	Υ		
data?				
Refer to section e) of guidance notes				
5.3 Does the site appear satisfactory in terms of fish welfare relating to sea lice infestation?	High	Υ		
f. Inspection of farm count procedures				
6.1 Are pens and fish sampled at random?	Low	V	CoGP Annex 6.	10 fish sampled from every cage each week.
6.2 Have the personnel conducting counts had appropriate training in	High	V	4.3.84-86, 5.3.53-55	10 harr sampled from every cage each week.
lice recognition and recording?	riigii		4.0.04-00, 0.0.00-00	
(Cross reference to training records – Section d)			1	
6.3 Can such personnel demonstrate post training competence?	High	Υ	CoGP 4.3.85, 5.3.54	
6.4 Do the sample sizes and methods of sampling match the CoGP	Medium	Y	Annex 6	Exceeds CoGP suggested protocol.
suggested protocol (detailed iii – vii)?				
N.B. Other strategies are acceptable if considered adequate in the				
control and reduction of sea lice				
6.5 Is identification and recording of sea lice count information	High	Υ	Annex 6	
including species and stages observed to be correct?				
Minimum recording requirements within the CoGP and NTS are:				
for Caligus elongatus all identifiable stages and for Lepeophtheirus				
salmonis chalimus, mobiles and adult females (with or without egg				
strings) <sup>11</sup>				
6.6 Is the transfer of data from field counts to records observed to be	Medium	Υ		
satisfactory?				
g. Inspection of treatment administration procedures	Lliah	NI/A		Treetments not absorved, but no both treetments conducted this evals
7.1 Are treatments considered to be administered in an appropriate competent manner?	High	N/A		Treatments not observed, but no bath treatments conducted this cycle.
Consider appropriate use of tarpaulins; completion of medication per				
prescription, correct concentrations, mixing and administrations,				
appropriate product used				
7.2 Is accurate information provided to the attending veterinary	High	Υ	CoGP 4.3.131, 5.3.85	Company vet has access to fish talk for up to date information.
surgeon for dosage calculation?				

Point for consideration	Risk level	Satisfactory?	Requirement	Comments and advice given or action taken if necessary
7.3 Are the fish under consideration being given any other medication, or are they in a withdrawal period for any other medication?		Υ		T.M.S. for lice counts and gill scores.
7.4 If so, has the prescribing veterinary surgeon been informed of this?	Medium	Υ	CoGP 4.3.132, 5.3.86	All info recorded on Fishtalk
7.5 Are clear instructions for medication, dosage and administration communicated to the staff responsible for treatment?	High	Υ	CoGP 4.3.133, 5.3.87	

Additional actions	Powers	Comments and advice given or action taken if necessary
h. FHI sea lice counts	Power granted under the Act	
If necessary conduct a sea lice count in accordance with the protocol of the CoGP. Indicate where this procedure has been done and make a record of results within the comments box	- section 3 (2) (a)	
i. Collection of samples	Power granted under the Act	
If necessary collect samples. Indicate if samples have been taken and detail what those samples are and the purpose of their collection	- section 3 (3) (a)	
j. Enforcement Notice.	Power granted under the Act	
If an enforcement notice has been issued then maintain a copy / duplicate and record detail	- Section 6 (2)	
Guidance on completing the Enforcement Notice		

- [1] Scottish Statutory Instrument The Fish Farming Businesses (Record Keeping) (Scotland) Order 2008
- [2] A Code of Good Practice for Scottish Finfish Aquaculture
- [3] Water temperature to be measured at the half way point of the depth of the facility containing the fish, or as close to as possible. For SW cage sites one reading per count may be s
- [4] Recording requirements:- for C. elongatus all identifiable stages and for L. salmonis mobiles and adult females (with or without egg strings)
- [5] Area refers to management area as specified within Part 3 of the industry CoGP or as redefined appropriately
- [6] For reference Annex 6 of the CoGP provides the detail of the NTS
- [7] FMA = Farm Management Area
- [8] FMS = Farm Management Statement
- [9] FMAg = Farm Management Agreement
- [10] No further action may be required when answering no to this point and yes to 3.18
- [11] Legal recording requirements within the SSI stipulate for Caligus elongatus: mobiles; and for Lepeophtheirus salmonis: non-gravid mobiles and gravid females.
- [12] VMD The Veterinary Medicines Regulations 2013 (SI 2013 No 2033)

Point for consideration Risk level Satisfactory? Requirement Comments and advice given or action taken if necessary

[13] AFSA - Aquaculture and Fisheries (Scotland) Act 2007 (as amended)

Case No:	2019-0388			Date of visit:	08/08/2019			
Site No:	FS1093			Inspector:				
Cho Ho.	. 01000	парсоют.						
Results Summary	Freq.	Date of Notification						
		Database	Insp	Phone	Insp	Writing	Insp	2 <sup>nd</sup> Insp
			<u> </u>					
					-			
							<b>-</b>	
								<b>-</b>
D 10								
Report Summary								
Case Type	Date	Insp	2 <sup>nd</sup> Insp					
SLA	11/02/2021							
	-							





Scottish Sea Farms Ltd Laurel House Laurelhill Business Park Polmaise Road Stirling FK7 9JQ

## FISH HEALTH INSPECTORATE VISIT REPORT

#### SUMMARY FOR INFORMATION OF SITE OPERATOR

 Business No
 FB0125
 Date of Visit
 08/08/2019

 Site No
 FS1093
 Site Name
 Teisti Geo

 Inspector
 Case No
 20190388

An enhanced sea lice inspection to ascertain the levels of sea lice and for assessing the measures in place for the prevention, control and reduction of sea lice was conducted in accordance with the Aquaculture and Fisheries (Scotland) Act 2007.

The visit consisted of an inspection of records with regards to sea lice, site procedures with regards to sea lice and the provision of advice.

### a) Inspection of sea lice records

The site meets the requirement of current Scottish industry best practice. There were no recommendations made and no further action is required.

### b) Inspection of records relating to treatment and control of sea lice

The site meets the requirement of current Scottish industry best practice. There were no recommendations made and no further action is required.

# c) Inspection of records relating to farm management groups and area management agreements.

The site meets the requirement of current Scottish industry best practice. There were no recommendations made and no further action is required.

## d) Inspection of records relating to training and procedures

The site meets the requirement of current Scottish industry best practice. No recommendations made or further action required.

## e) Inspection of site and site stock

The site meets the requirement of current Scottish industry best practice. No recommendations made or further action required.

## f) Inspection of farm count procedures

An inspection of site staff conducting and recording a sea lice count was carried out. This met the requirements of The Fish Farming Business (Record Keeping) (Scotland) Order 2008 and CoGP. No further recommendations or further action required.

## g) Inspection of treatment administration procedures

Procedures were not inspected as a treatment was not taking place at the time of inspection. However, discussions on procedures with the site manager would suggest that the site meets the requirement of current Scottish industry best practice.

Please contact myself or the duty inspector should you require any further information or have any queries regarding this report.



Signed: Date: 11/02/21

Fish Health Inspector

The Fish Health Inspectorate Service Charter detailing standards of service is available on the Marine Scotland website at <a href="https://www.gov.scot/Topics/marine/Fish-Shellfish/FHI/charter">www.gov.scot/Topics/marine/Fish-Shellfish/FHI/charter</a>